Welcome to our dedicated page for Ngm Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals stock.
NGM Biopharmaceuticals, Inc. (NGM) has described itself as a biotechnology company focused on discovering and developing novel, life-changing medicines, with all product candidates generated by its in-house discovery engine. The NGM Bio news flow reflects this biology-centric strategy across oncology, liver disease and rare conditions, as well as significant corporate developments affecting the former NGM stock listing.
News coverage for NGM Bio includes updates on its solid tumor oncology programs, such as clinical data from the ongoing Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA (pembrolizumab) in advanced or metastatic solid tumors. The company has also reported progress on NGM831 and NGM438, antagonist antibody product candidates targeting ILT3 and LAIR1, respectively, in combination with pembrolizumab.
Investors and observers can also find news items detailing NGM Bio’s work in liver and metabolic diseases, including positive Phase 2b results from the ALPINE 4 trial of aldafermin, an engineered FGF19 analog, in patients with compensated cirrhosis due to NASH, and plans to further develop aldafermin for primary sclerosing cholangitis. Additional updates have covered the potential development of NGM120, a GDF15/GFRAL antagonist antibody product candidate, for hyperemesis gravidarum, a rare and serious pregnancy-related condition.
Another important theme in NGM Bio news is corporate and transaction activity. The company announced an Agreement and Plan of Merger with Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc., affiliates of The Column Group, LP, followed by the closing of a cash tender offer and subsequent merger that resulted in NGM Bio becoming a privately held, wholly-owned subsidiary and its common stock ceasing to trade on Nasdaq.
By reviewing the NGM news feed, readers can track historical announcements on clinical data presentations, conference participation, strategic updates on pipeline prioritization, and the steps that led to the going-private transaction. This provides context on how NGM Bio’s scientific programs and corporate structure have evolved over time.
NGM Biopharmaceuticals (NGM) announced the expansion of its oncology portfolio with NGM707, a novel dual antagonist antibody targeting ILT2 and ILT4, which may enhance anti-tumor immune responses. First-in-human testing is planned for mid-2021. NGM707 aims to combat myeloid cell immune suppression implicated in immune evasion by tumors. This new candidate complements NGM120, currently in clinical trials. NGM's R&D Day is scheduled for December 9, 2020, to showcase its pipeline, which addresses various diseases, including cancer.
NGM Biopharmaceuticals (NGM) announced positive results from its 24-week Phase 2 study of aldafermin in patients with non-alcoholic steatohepatitis (NASH). The study showed a statistically significant reduction in liver fat content and improvements in liver fibrosis, with a favorable safety profile. Notably, 30% of patients with advanced liver fibrosis (F3) exhibited significant fibrosis improvement. NGM plans to report topline data from its Phase 2b ALPINE 2/3 study in Q2 2021, aiming to further validate aldafermin's potential as a transformative treatment for NASH.
NGM Biopharmaceuticals, Inc. (NGM) announced that data from its 24-week Phase 2 study of aldafermin in non-alcoholic steatohepatitis (NASH) will be presented at The Digital International Liver Congress 2020 from August 27-29. The presentation includes positive topline results and new analyses. Additionally, several related poster presentations will showcase findings on biomarkers and improvements in non-invasive tests due to aldafermin therapy. This highlights NGM's ongoing commitment to developing transformative therapeutics for liver diseases.
NGM Biopharmaceuticals (NGM), a biotechnology company, has announced that CEO David J. Woodhouse, Ph.D., will present a business update at two upcoming investor conferences. The presentations will take place on August 10, 2020, at the BTIG Biotechnology Conference at 11:00 am ET, and on August 13, 2020, at the Canaccord Genuity 40th Annual Growth Conference at 9:00 am ET. A live webcast of these presentations will be available on NGM's website, with a replay accessible for 30 days post-event.
NGM Biopharmaceuticals, focused on transformative therapeutics, announced that CEO David J. Woodhouse will present an overview and business update at two investor conferences. The events are scheduled for June 3, 2020, at the Jefferies Virtual Healthcare Conference at 3:30 pm ET, and June 10, 2020, at the Goldman Sachs 41st Annual Global Healthcare Conference at 1:20 pm ET. A live webcast will be available on their website, with a replay accessible for 30 days post-event.
NGM Biopharmaceuticals will host its 2020 Annual Meeting of Stockholders as a virtual-only event on May 20, 2020, at 7:30 a.m. PDT due to COVID-19 safety concerns. Stockholders of record as of March 23, 2020, can participate via a live audio webcast, starting at 6:30 a.m. PDT. The company emphasizes the same rights for stockholders as in-person attendance. Instructions for participation, voting, and accessing the meeting are detailed, with a reminder to submit proxies in advance. The meeting will be archived for one year.